Safety Differences Across Androgen Receptor Inhibitors in Nonmetastatic Castration-Resistant Prostate Cancer

Authors:

Abstract
Approval of apalutamide, enzalutamide and darolutamide has transformed the treatment landscape and guideline recommendations for patients with nonmetastatic castration-resistant prostate cancer but... Plain language summary Prostate cancer is one of the most common cancers in men. Because male hormones fuel the growth of prostate cancer cells, initial treatments generally focus on reducing these... Tweetable abstract Key safety differences exist among second-generation androgen receptor inhibitors for nonmetastatic castration-resistant prostate cancer. We discuss these differences and their p...
Funding Information
  • Bayer

This publication has 53 references indexed in Scilit: